Intensive care medicine

EQS-News: AdrenoMed Receives FDA Fast Track Designation for Enibarcimab for Treatment of Septic Shock

Retrieved on: 
星期三, 四月 10, 2024
Sepsis, Communication, Patient, Public, Fast Track, Adrenomedullin, Biomarker, Accelerated approval (FDA), Mortality, Septic shock, Death, DPP3, Septic, Medicine, Priority review, Organ dysfunction, Intensive care medicine, CMO, Collection, FDA, Infection, RCI, Food, Pharmaceutical industry

AdrenoMed is now preparing a confirmatory Phase IIb/III clinical trial to confirm the reduced septic shock mortality under enibarcimab treatment employing a precision medicine approach.

Key Points: 
  • AdrenoMed is now preparing a confirmatory Phase IIb/III clinical trial to confirm the reduced septic shock mortality under enibarcimab treatment employing a precision medicine approach.
  • AdrenoMed’s CEO Dr. Richard Jones commented: “We are very pleased that enibarcimab has received Fast Track designation from the FDA, recognizing its potential as an innovative biomarker-guided treatment against septic shock to fill the unmet medical need in this very serious condition with a high death toll.
  • With a mortality rate of 20-30% for sepsis [1] and 30%-50% for septic shock in developed countries, [2] sepsis represents an enormous public health burden and is responsible for almost 20% of all deaths worldwide.
  • Dr. Stephan Witte, CMO of AdrenoMed, said: “We are very confident that the use of enibarcimab in combination with two biomarkers, Adrenomedullin (bio-ADM) and circulating dipeptidyl peptidase 3 (cDPP3), holds the promise to become the first effective targeted treatment against septic shock.

To Bolster Global Efforts in Combating Antibiotic-Resistant Bacteria KFSH&RC Scientists Discover New Bacteria Species: Riyadhensis

Retrieved on: 
星期一, 三月 25, 2024
WGS, Health, Disease, Education, Patient, Research, Hospital, Bacteria, Pseudomonas aeruginosa, RC, KFSH, Infection, Intensive care medicine, Newsweek, ICU, Vaccine

RIYADH, Saudi Arabia, March 25, 2024 (GLOBE NEWSWIRE) -- In a ground-breaking development, scientists at King Faisal Specialist Hospital and Research Centre (KFSH&RC) have identified a new species of bacteria, referred to as "Stenotrophomonas Riyadhensis" through the application of whole-genome sequencing (WGS) technology. This discovery signifies a major advancement in understanding how bacteria interact with existing drugs, paving the way for innovative therapeutic strategies. Such efforts are essential in the global fight against antibiotic-resistant bacteria, highlighting KFSH&RC’s advanced research capabilities and its leading role in fostering scientific discoveries and enhancing patient care.

Key Points: 
  • This discovery signifies a major advancement in understanding how bacteria interact with existing drugs, paving the way for innovative therapeutic strategies.
  • Such efforts are essential in the global fight against antibiotic-resistant bacteria, highlighting KFSH&RC’s advanced research capabilities and its leading role in fostering scientific discoveries and enhancing patient care.
  • This represents substantial progress in combating antibiotic resistance, developing pharmaceuticals, and preventing the spread of diseases.
  • Furthermore, this approach lays the groundwork for scientific collaboration at all levels, enhancing global efforts to combat antibiotic resistance.

FDA Grants HemoSonics Expanded Use of its Critical Bleeding Management System with Special 510(k) Clearance

Retrieved on: 
星期三, 四月 3, 2024
Patient, Trauma, Hospital, Acquisition, Coagulopathy, Cartridge, Operating, Hemostasis, American Red Cross, Bleeding, Intensive care medicine, FDA, Liver, Journal of Cardiothoracic Surgery, Food, Medical device

DURHAM, N.C., April 3, 2024 /PRNewswire/ -- HemoSonics, a medical device company focused on acute bleeding management, today announced it has received Special 510(k) clearance from the U.S. Food and Drug Administration (FDA) for the expanded use of arterial blood samples with its Quantra QStat® Cartridge. HemoSonics' QStat Cartridge used with the Quantra Hemostasis Analyzer first received 510(k) clearance from the U.S. FDA in 2022 for use in venous whole blood samples. Today's announcement enables hospitals to further standardize and operationalize viscoelastic testing with an arterial and venous indication for both HemoSonics' QStat Cartridge and the QPlus® Cartridge.

Key Points: 
  • HemoSonics' Quantra® Hemostasis Analyzer provides comprehensive blood analysis that details critical bleeding disorders and helps clinicians manage patients back into hemostasis.
  • DURHAM, N.C., April 3, 2024 /PRNewswire/ -- HemoSonics , a medical device company focused on acute bleeding management, today announced it has received Special 510(k) clearance from the U.S. Food and Drug Administration (FDA) for the expanded use of arterial blood samples with its Quantra QStat® Cartridge.
  • HemoSonics' QStat Cartridge used with the Quantra Hemostasis Analyzer first received 510(k) clearance from the U.S. FDA in 2022 for use in venous whole blood samples.
  • "The Quantra System now has the broadest range of FDA-cleared clinical indications of any cartridge-based viscoelastic testing system.

UNC Health Blue Ridge Advances Innovation with MEDI+SIGN Digital Whiteboards

Retrieved on: 
星期一, 三月 25, 2024
RN, Communication, Environment, UNC Health Blue Ridge, EMR, Patient, UNC, Intensive care unit, Navigation, Patient experience, Diet, MSN, Infection, Intensive care medicine, Workload, Nursing, Patient safety

SMITHSBURG, Md., March 25, 2024 /PRNewswire-PRWeb/ -- UNC Health Blue Ridge outfits its new intensive care units with some of the best technology available, including the implementation of MEDI+SIGN Digital Whiteboards and MEDI+SIGN Digital Door Displays, keeping with its commitment to providing the very best in healthcare for the region.

Key Points: 
  • "- Jon Mercer, Chief Operating Officer at UNC Health Blue Ridge.
  • The implementation of MEDI+SIGN is a testament to UNC Health Blue Ridge's commitment to the community and patients they serve.
  • The critical care rooms at UNC Health Blue Ridge feature fully automated 43" digital in-room whiteboards and 15.6" digital door displays to present real-time healthcare data to clinicians, patients, and their families.
  • Jon Mercer, Chief Operating Officer at UNC Health Blue Ridge, sums it up nicely - "The electronic boards are exciting, innovative, patient-centric, and important to enhancing the care we provide."

HemoSonics Named to Fast Company's 2024 World's Most Innovative Companies List

Retrieved on: 
星期四, 三月 21, 2024
Organization, Blood transfusion, Novartis, Patient, Hospital, AI, Hope, Bristol Myers Squibb, Operating, Cartridge, Intensive care medicine, Amgen, Blood, FDA, Medicine, Pharmaceutical industry

DURHAM, N.C. , March 21, 2024 /PRNewswire/ -- HemoSonics, a medical device company focused on acute bleeding management, today announced it has been named to the prestigious list of Fast Company's Most Innovative Companies for 2024. The annual Fast Company flagship awards spotlight companies at the forefront of their respective industries and recognize organizations and products that are transforming industries through their innovations, setting new standards, and achieving remarkable milestones that are moving the world forward. HemoSonics joins previous Fast Company Most Innovative Company winners, including Abbott, Bristol Myers Squib, Novartis, Amgen, Scopio Labs and others.

Key Points: 
  • HemoSonics joins previous Fast Company Most Innovative Company winners, including Abbott, Bristol Myers Squib, Novartis, Amgen, Scopio Labs and others.
  • The World's Most Innovative Companies is Fast Company's hallmark franchise and one of the year's most anticipated awards for groundbreaking innovations.
  • Fast Company's editorial team identified the 2024 Most Innovative Companies driving progress worldwide and across industries, evaluating thousands of submissions through a competitive application process.
  • We face daunting challenges on many fronts, but the solutions we celebrate in Most Innovative Companies give me plenty of hope about the future."

Volition appoints Dr Andrew Retter as Chief Medical Officer

Retrieved on: 
星期二, 三月 19, 2024
NHS foundation trust, Thrombosis, Sepsis, Guy, Disease, Neutrophil extracellular traps, Consultant, Patient, Research, Intensive care medicine, Respiratory failure, ECMO, NETS, Cancer, Heart, Nursing care plan, Clinical governance, Nursing

HENDERSON, Nev., March 19, 2024 /PRNewswire/ -- VolitionRx Limited (NYSE AMERICAN: VNRX) ("Volition"), a multi-national epigenetics company, has appointed Dr Andrew Retter as its Chief Medical Officer, effective April 1, 2024.

Key Points: 
  • HENDERSON, Nev., March 19, 2024 /PRNewswire/ -- VolitionRx Limited (NYSE AMERICAN: VNRX) ("Volition"), a multi-national epigenetics company, has appointed Dr Andrew Retter as its Chief Medical Officer, effective April 1, 2024.
  • Dr Retter will provide medical leadership at Volition and ensure the company's scientific and clinical efforts are aligned with patient needs.
  • Cameron Reynolds, President and Group Chief Executive Officer at Volition, said: "We are delighted to welcome Andrew to Volition.
  • As Chief Medical Officer he will be vital to our success – ensuring the needs of the patient are placed at the heart of our research, development and commercialization activities."

Fresenius Medical Care launches "Augmented Reality" for training on Kidney Replacement Therapy device

Retrieved on: 
星期二, 三月 19, 2024
Ready4, Fresenius Medical Care, Learning, Safety, Kidney, Augmented reality, Education, Knowledge, Hospital, Emergency medicine, Augment, Intensive care medicine, Dialysis, FME, BAD, ICU, Nursing, Health, Medtech

The glasses stream visual and acoustic recordings as users interact with the dialysis machine, providing professionals with an immersive learning experience.

Key Points: 
  • The glasses stream visual and acoustic recordings as users interact with the dialysis machine, providing professionals with an immersive learning experience.
  • Our innovative solution is designed to ensure that nursing staff, particularly those in Intensive Care Units, are equipped with the knowledge needed to provide high-quality and exceptional patient care," says Dr. Katarzyna Mazur-Hofsäß, member of the Management Board of Fresenius Medical Care AG and responsible for Care Enablement, Fresenius Medical Care's MedTech segment.
  • The AR glasses provide access to the Augmented Reality learning program Ready4 multiFiltratePRO AR, which Fresenius Medical Care presented today at the International Symposium on Intensive Care and Emergency Medicine (ISICEM) in Brussels.
  • Ready4 multiFiltratePRO AR has been specifically developed for use with the multiFiltratePRO, Fresenius Medical Care's Continuous Kidney Replacement Therapy system.

Cytovale's Rapid Sepsis Diagnostic Test Demonstrates Improved Patient Care and Cost Savings in Hospital Application

Retrieved on: 
星期二, 三月 19, 2024
Diagnosis, Sepsis, Conference, Infection, Risk, Patient, SAN, Food and Drug Administration, Hospital, Emergency medicine, Triage, Death, Intensive care medicine, Emergency department, Critical care, ED, Hospice and palliative medicine, Food, FDA, Health, Pharmaceutical industry

The test generates results in about 8 minutes using a standard blood draw, and can be seamlessly and efficiently integrated into existing care workflows.

Key Points: 
  • The test generates results in about 8 minutes using a standard blood draw, and can be seamlessly and efficiently integrated into existing care workflows.
  • Compared to controls, patients whose care was informed by IntelliSep testing spent less time in the hospital and benefited from more efficient triage, resulting in significant cost savings.
  • On average, the study showed that IntelliSep-informed care led to cost savings of:
    Taken together, this study showed an average cost savings of $1,429 per patient across the entire IntelliSep tested cohort.
  • The combination of cost savings for our patients, paired with a faster time to return home to their families, is a game changer."

New publication demonstrates 100% reduction in pressure injuries for all patients - regardless of skin tone : Arjo Inc.

Retrieved on: 
星期三, 三月 13, 2024
Incidence, Patient, Intensive care medicine, Journal, Nursing, Pressure, Tetraplegia, Skin, Veteran, Cosmetics

As mentioned within the publication "Reported hospital acquired pressure injury incidence rates are much higher in special care settings, including intensive/critical care, medical/surgical care and in individual population groups, including dark skin patients and veterans with spinal cord injuries."

Key Points: 
  • As mentioned within the publication "Reported hospital acquired pressure injury incidence rates are much higher in special care settings, including intensive/critical care, medical/surgical care and in individual population groups, including dark skin patients and veterans with spinal cord injuries."
  • The findings highlight disparity in pressure injury incidence rate amongst dark tone skin patients compared to light skin tone patients.
  • The results of this project showed a 100% reduction in pressure injuries for all patients over the twelve-week period using the Provizio SEM Scanner as an adjunct to current standard of care for all patients, regardless of the patient's skin tone.
  • Notably, 70% of patients in the cohort had dark tone skin highlighting the importance of this skin tone agnostic technology.

Community Health Systems Partners With Mark Cuban Cost Plus Drug Company to Address the Rising Cost of Drugs and Potential Drug Shortages

Retrieved on: 
星期四, 三月 7, 2024
Managed Care, Hospitals, Pharmaceutical, Health, CYH, Hospital, Cost Plus Drugs, Doctor of Philosophy, MD, Partnership, Food, CHS, Norepinephrine, World Market (store), Community Health Systems, Intensive care medicine, ERS, Patient, Adrenaline, Patient safety, Community, Pharmaceutical industry

Community Health Systems, Inc. (NYSE: CYH) (CHS) will become the first national healthcare system to purchase select pharmaceutical supplies from Mark Cuban Cost Plus Drug Company (Cost Plus Drugs) as part of a new, collaborative relationship that promises to bring high-quality, lower cost drugs into the hospital setting.

Key Points: 
  • Community Health Systems, Inc. (NYSE: CYH) (CHS) will become the first national healthcare system to purchase select pharmaceutical supplies from Mark Cuban Cost Plus Drug Company (Cost Plus Drugs) as part of a new, collaborative relationship that promises to bring high-quality, lower cost drugs into the hospital setting.
  • Drug shortages – Cost Plus Drugs is focused on manufacturing drugs that are often in limited supply, threatening patient treatment and outcomes when shortages occur.
  • CHS and Cost Plus Drugs are working together to identify, prepare for, and mitigate potential future drug shortages in the hospital setting.
  • “Community Health Systems has stepped forward to consider important issues related to drug supply, drug costs, patient care and outcomes,” said Alex Oshmyansky, MD, PhD, Chief Executive Officer of Mark Cuban Cost Plus Drug Company.